Unravelling 5-oxoprolinuria (pyroglutamic aciduria) due to bi-allelic OPLAH mutations: 20 new mutations in 14 families

Jörn Oliver Sass, Corinne Gemperle-Britschgi, Maja Tarailo-Graovac, Nisha Patel, Melanie Walter, Albena Jordanova, Majid Alfadhel, Ivo Barić, Mahmut Çoker, Aynur Damli-Huber, Eissa Ali Faqeih, Nuria García Segarra, Michael T. Geraghty, Bjørn Magne Jåtun, Sema Kalkan Uçar, Merten Kriewitz, Markus Rauchenzauner, Karmen Bilić, Ivailo Tournev, Claudia TillBryan Sayson, Daniel Beumer, Cynthia Xin Ye, Lin-Hua Zhang, Hilary Vallance, Fowzan S. Alkuraya, Clara D. M. van Karnebeek

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)

Abstract

Primary 5-oxoprolinuria (pyroglutamic aciduria) is caused by a genetic defect in the gamma-glutamyl cycle, affecting either glutathione synthetase or 5-oxoprolinase. While several dozens of patients with glutathione synthetase deficiency have been reported, with hemolytic anemia representing the clinical key feature, 5-oxoprolinase deficiency due to OPLAH mutations is less frequent and so far has not attracted much attention. This has prompted us to investigate the clinical phenotype as well as the underlying genotype in patients from 14 families of various ethnic backgrounds who underwent diagnostic mutation analysis following the detection of 5-oxoprolinuria. In all patients with 5-oxoprolinuria studied, bi-allelic mutations in OPLAH were indicated. An autosomal recessive mode of inheritance for 5-oxoprolinase deficiency is further supported by the identification of a single mutation in all 9/14 parent sample sets investigated (except for the father of one patient whose result suggests homozygosity), and the absence of 5-oxoprolinuria in all tested heterozygotes. It is remarkable, that all 20 mutations identified were novel and private to the respective families. Clinical features were highly variable and in several sib pairs, did not segregate with 5-oxoprolinuria. Although a pathogenic role of 5-oxoprolinase deficiency remains possible, this is not supported by our findings. Additional patient ascertainment and long-term follow-up is needed to establish the benign nature of this inborn error of metabolism. It is important that all symptomatic patients with persistently elevated levels of 5-oxoproline and no obvious explanation are investigated for the genetic etiology. (C) 2016 Elsevier Inc. All rights reserved
Original languageEnglish
Pages (from-to)44-49
JournalMolecular Genetics and Metabolism
Volume119
Issue number1-2
DOIs
Publication statusPublished - 2016

Cite this